Trial Profile
FluLaval Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With FluLaval Quadrivalent During Pregnancy or Within 28 Days Preceding Conception
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 2282512A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 23 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 13 Dec 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Dec 2013 New trial record